New therapies for heart failure: is thalidomide the answer?
Open Access
- 1 May 2000
- journal article
- review article
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 93 (5) , 305-311
Abstract
The syndrome of advanced heart failure is associated with considerable morbidity and mortality. Ideas about the reasons for the progressive nature of the heart failure syndrome have changed over the years, with the initial view that progression was principally due to pump failure (the ‘haemodynamic’ hypothesis), giving way to more modern views, which implicate neuro‐endocrine activation (including catecholamine excess, renin‐angiotensin system activation, etc.). More recently, an excess of inflammatory cytokines has been found in advanced heart failure and implicated in the progression of the disease. Amongst the cytokines found, TNF‐α seems to be particularly important. The principle therapeutic action of thalidomide appears to be reduction of TNF‐α levels. We therefore suggest that there may be a role for thalidomide, or its derivatives, in the management of advanced heart failure.Keywords
This publication has 58 references indexed in Scilit:
- Thalidomide — A Revival StoryNew England Journal of Medicine, 1999
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Hormones and Hemodynamics in Heart FailureNew England Journal of Medicine, 1999
- Endotoxin and immune activation in chronic heart failure: a prospective cohort studyThe Lancet, 1999
- Genotyping for polymorphisms in interferon-γ, interleukin-10, transforming growth factor-β1 and tumour necrosis factor-α genes: a technical reportTransplant Immunology, 1998
- Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathyThe Lancet, 1998
- Thalidomide as an Anti-TNF-α Inhibitor: Implications for Clinical UseClinical Immunology and Immunopathology, 1996
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.Journal of Experimental Medicine, 1993